These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31918581)

  • 1. Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
    Navar AM; Mulder HM; Wojdyla DM; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006019. PubMed ID: 31918581
    [No Abstract]   [Full Text] [Related]  

  • 2. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
    J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
    Banach M; Penson PE
    Cardiovasc Res; 2019 Mar; 115(3):e26-e31. PubMed ID: 30605511
    [No Abstract]   [Full Text] [Related]  

  • 4. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
    Handelsman Y; Lepor NE
    J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421
    [No Abstract]   [Full Text] [Related]  

  • 5. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.
    Virani SS; Akeroyd JM; Nambi V; Michos ED; Morris PB; Nasir K; Smith SC; Stone NJ; Petersen LA; Ballantyne CM
    Circulation; 2019 Jan; 139(3):410-412. PubMed ID: 30586689
    [No Abstract]   [Full Text] [Related]  

  • 6. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
    Colivicchi F; Massimo Gulizia M; Arca M; Luigi Temporelli P; Gonzini L; Venturelli V; Morici N; Indolfi C; Gabrielli D; De Luca L
    Cardiovasc Ther; 2020; 2020():3856242. PubMed ID: 31969932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.
    Colantonio LD; Monda KL; Rosenson RS; Brown TM; Mues KE; Howard G; Safford MM; Yedigarova L; Farkouh ME; Muntner P
    Cardiovasc Drugs Ther; 2019 Apr; 33(2):189-199. PubMed ID: 30746585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C; Kelly MS; Shapiro MD; Dixon DL
    J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PCSK9 revolution: Current status, controversies, and future directions.
    Warden BA; Fazio S; Shapiro MD
    Trends Cardiovasc Med; 2020 Apr; 30(3):179-185. PubMed ID: 31151804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of PCSK9 Inhibitors in Practice.
    Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
    Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B; Jubran A
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Patients for Nonstatin Therapy.
    Robinson JG; Watson KE
    Rev Cardiovasc Med; 2018; 19(S1):S1-S8. PubMed ID: 30207552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V
    Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract]   [Full Text] [Related]  

  • 15. PCSK9 inhibitor valuation: A science-based review of the two recent models.
    Baum SJ; Cannon CP
    Clin Cardiol; 2018 Apr; 41(4):544-550. PubMed ID: 29512936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonstatin Therapy for Dyslipidemia.
    Ahmed HM; Nissen SE
    Circ Res; 2018 Oct; 123(9):1036-1038. PubMed ID: 30355163
    [No Abstract]   [Full Text] [Related]  

  • 18. Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data.
    Passero LE; Roberts MC
    High Blood Press Cardiovasc Prev; 2024 Mar; 31(2):215-219. PubMed ID: 38308804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.